GSK Shutters Plant on Bacteria Concerns

GlaxoSmithKline has temporarily shuttered a plant in the US state of North Carolina that produces inhaled medications after routine testing found the bacteria that causes Legionnaire's disease in a self-standing cooling tower.

A spokesperson for the plant near the state capital of Raleigh said testing is conducted every three months, but the company was seeking "more details on whether product has been impacted” and determining the procedure for handling it.

The facility produces inhaled drugs such as the asthma treatment Advair, and also toll manufactures for other pharmaceutical companies. Local officials said they were not aware of any Legionnaire's disease cases associated with the Glaxo plant.

According to reports, the same bacteria was found in cooling tanks in the Bronx borough of New York City earlier this summer, which is believed to have caused 12 deaths from Legionnaires' disease.

The US Centers for Disease Control and Prevention, based in Atlanta, Georgia, said about 8,000 to 18,000 Americans are hospitalized with the illness annually.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.